Cyclophosphamide: all 1,616 studies that test it
Page 12 of 17. Open to participants first (256), then studies with results posted, then the rest; newest registration first within each.
- Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS TumorsCompletedNCT02390843Phase 1
- Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to People With Thyroglobulin Expressing Thyroid CancerWithdrawnNCT02390739Phase 1/2
- Vaccination in Prostate Cancer (VANCE)CompletedNCT02390063Phase 1
- Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid TumorsActive, not recruitingNCT02389309Phase 1
- A Phase I Study of T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728mR in HIV-Infected PatientsCompletedNCT02388594Phase 1
- HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIACompletedNCT02379520Phase 1
- Randomized CT to Evaluate Efficacy of Neoadjuvant Chemotherapy Customized by Levels of BRCA1-HER2 Negative Breast CancerCompletedNCT02365805Phase 2
- CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple MyelomaStatus unknownNCT02362165Phase 3
- A Study of SGT-53 in Children With Refractory or Recurrent Solid TumorsSuspendedNCT02354547Phase 1
- A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing DLBCLTerminatedNCT02323230Phase 2
- Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory NeuroblastomaActive, not recruitingNCT02298348Phase 1
- Low Dose Metronomic Poly-chemotherapy for Metastatic CRCCompletedNCT02280694Phase 2
- Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic MelanomaCompletedNCT02278887Phase 3
- HER2-Peptide Vaccination of Patients With Solid TumorsCompletedNCT02276300Phase 1
- Infusion of Allogeneic, 3rd Party CD19-specific T CellsWithdrawnNCT02274506Phase 1
- Maintenance Bevacizumab Only or Bevacizumab Plus Metronomic Chemotherapy in Advanced Colorectal CancerCompletedNCT02271464Phase 2
- MSC and Cyclophosphamide for Acute Graft-Versus-Host Disease (aGVHD) ProphylaxisStatus unknownNCT02270307Phase 2/3
- Carfilzomib, Cyclophosphamide, Dexamethasone in Transplant Eligible Newly Diagnosed High-risk Multiple MyelomaCompletedNCT02217163Phase 2
- Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Eribulin Chemotherapy (ACE) in Operable HER2-negative Breast CancerWithdrawnNCT02215876Phase 2
- Cyclophosphamide With Biochemical Progression During Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma (MM)CompletedNCT02206503Phase 2
- Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma PatientsCompletedNCT02206425Phase 1/2
- Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma PatientsCompletedNCT02204241Phase 1/2
- Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma.CompletedNCT02203643Phase 2
- Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)WithdrawnNCT02194374Phase 1
- Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Metastatic Triple-negative Breast CancerTerminatedNCT02183805Phase 2
- Intra-Osseous Co-Transplant of UCB and hMSCCompletedNCT02181478Early Phase 1
- Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk NeuroblastomaActive, not recruitingNCT02176967Phase 3
- Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple MyelomaCompletedNCT02176213Phase 2
- Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor SourceCompletedNCT02167958Phase 1
- Conventional Dose Versus High Dose Sequential Chemotherapy for Poor Prognosis Germ Cell TumorsCompletedNCT02161692Phase 2
- Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic LeukemiaActive, not recruitingNCT02153580Phase 1
- Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic MalignanciesCompletedNCT02122081Phase 1
- A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid TumorsCompletedNCT02107963Phase 1
- Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Risk ALL or AMLActive, not recruitingNCT02094794Phase 2
- Tolerability and Efficacy of Modified VCD Regimens in Previously Untreated Multiple Myeloma.Status unknownNCT02086942Phase 2
- Bortezomib, Dexamethasone, and Cyclophosphamide in Treating Older Patients With Multiple MyelomaWithdrawnNCT02082405Phase 2
- NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell LiposarcomaWithdrawnNCT02059850Phase 1
- Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT02057770Phase 1
- Reduced Intensity Conditioning (RIC) Regimen and Post-transplant Cyclophosphamide in Haploidentical Bone Marrow Transplantation in in Patients With Poor Prognosis LymphomasStatus unknownNCT02049580Phase 2
- Phase II Multicenter, Open-label, Single Arm Clinical Study of Pomalidomide and dexamethasonE and CyclophosphamideCompletedNCT02046915Phase 2
- N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/TopotecanCompletedNCT02030964Phase 1
- Combination of G-CSF, Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Multiple MyelomaStatus unknownNCT02027220Phase 2
- Study of Sequential High-dose Chemotherapy in Children With High Risk MedulloblastomaTerminatedNCT02025881Phase 1/2
- Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation in Children and AdolescentsStatus unknownNCT02014506Phase 1/2
- Moderate-dose Cyclophosphamide for Childhood Acquired Aplastic AnemiaStatus unknownNCT01995331Phase 4
- Bevacizumab in Combination With Chemotherapy in the Neo-adjuvant Setting for HER2 (-) Breast CancerTerminatedNCT01985841Phase 2
- Prospective, Multicentric, Phase II Randomized Controlled Trial on Two Parallel Groups Comparing the Efficacy of Two Immunosuppressive Drugs (methotrexate, Cyclophosphamide) in Large Granular Lymphocytes LeukemiaCompletedNCT01976182Phase 2
- Comparative Study of Rituximab Versus Combination of Rituximab and Intravenous Cyclophosphamide in Severe PemphigusStatus unknownNCT01974518Phase 3
- Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone as Induction Treatment in the Initial Management of Multiple Myeloma (IFM2013-04)CompletedNCT01971658Phase 3
- Induction Preoperative Chemotherapy for Patients With Locally Advanced Triple Negative Breast CancerCompletedNCT01969032Phase 2
- iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and NeuroblastomaActive, not recruitingNCT01953900Phase 1
- Stereotactic Body Radiation Therapy and T-Cell Infusion in Treating Patients With Metastatic Kidney CancerTerminatedNCT01943188Phase 1
- A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic LeukemiaActive, not recruitingNCT01920737Phase 2
- A Phase II Trial of Adjuvant Radiotherapy Combined With Chemotherapy for Patients With High-risk Endometrial CancerCompletedNCT01918124Phase 2
- Phase II Pilot Study Assessing Efficacy of a Cisplatin - Metronomic Cyclophosphamide Treatment in Patients With Metastatic Triple Negative Breast Cancer Resistant to Anthracyclines and TaxanesTerminatedNCT01910870Phase 2
- Phase II Pilot Study Assessing Efficacy of a Cisplatin - Métronomic Cyclophosphamide Treatment in Patients With Stade IV Triple Negative Breast Cancer Secondary Resistant to Anthracyclines and TaxanesTerminatedNCT01910844Phase 2
- A Trail of Neoadjuvant Endostar in Combination With Chemotherapy in Breast CancerStatus unknownNCT01907529Phase 2/3
- ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma MultiformeActive, not recruitingNCT01903330Phase 2
- Myocet + Cyclophosphamide + Metformin Vs Myocet + Cyclophosphamide in 1st Line Treatment of HER2 Neg. Metastatic Breast Cancer PatientsCompletedNCT01885013Phase 2
- Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With MelanomaCompletedNCT01883323Phase 2
- Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)CompletedNCT01868269Phase 3
- Low-dose VS High-dose IV Cyclophosphamide for Proliferative LN in ChildrenTerminatedNCT01861561Phase 4
- Study of Weekly Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients (wCCyd)CompletedNCT01857115Phase 1/2
- Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)CompletedNCT01839097Phase 1
- High-dose Cyclophosphamide for Severe Refractory Crohn DiseaseWithdrawnNCT01836289Phase 1/2
- Low-dose Cyclophosphamide and Outpatient IV Interleukin-2 in Metastatic MelanomaWithdrawnNCT01833767Phase 2
- 3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAINActive, not recruitingNCT01822652Phase 1
- NY-ESO-1 T Cells in OG CancerTerminatedNCT01795976Phase 2
- First Line Treatment Trial in Multiple Myeloma, Finnish Myeloma Group- Multiple Myeloma 02CompletedNCT01790737Phase 2
- A Study of Improving the Efficacy of Treatment in High Risk T Cell Lymphoma PatientsStatus unknownNCT01788137Phase 3
- Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's MacroglobulinemiaCompletedNCT01788020Phase 3
- ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast CancerCompletedNCT01779206Phase 2/3
- Dose Adjusted EPOCH-R, to Treat Mature B Cell MalignanciesCompletedNCT01760226Early Phase 1
- Haploidentical Stem Cell Transplantation for Children With Acquired Severe Aplastic AnemiaStatus unknownNCT01759732Phase 2
- Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA NephropathyStatus unknownNCT01758120Phase 4
- Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD ProphylaxisTerminatedNCT01749111Phase 3
- Anti-cancer MUC1-specific Immunotherapy for Unresectable Stage III Non-small Cell Lung CancerWithdrawnNCT01731587Phase 1
- Clinical Study of Metronomic Oral Cyclophosphamide in Patients With Advanced SarcomasCompletedNCT01716689Phase 2
- PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast CancerTerminatedNCT01697293Phase 1/2
- Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01689987Phase 1
- Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic LeukemiaCompletedNCT01681563Phase 2
- High Dose Chemo With Stem Cell Transplant as Treatment for Multiple Sclerosis That Failed Prior TreatmentTerminatedNCT01679041Phase 2
- Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute LeukemiaWithdrawnNCT01677949Phase 2
- Sirolimus With Cyclophosphamide and Topotecan for Pediatric/Adolescent Relapsed and Refractory Solid TumorsCompletedNCT01670175Phase 1
- Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid TumorsCompletedNCT01661400Phase 1
- A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed MyelomaCompletedNCT01660750Phase 1
- CD19-specific T-cell for Chronic Lymphocytic Leukemia (CLL)CompletedNCT01653717Phase 1
- Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune DeficienciesActive, not recruitingNCT01652092Not applicable
- "Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer"Status unknownNCT01641406Phase 2
- Cyclophosphamide Therapy for Refractory Antibody-Mediated Rejection (AMR) in Kidney TransplantsTerminatedNCT01630538Phase 2
- NK Cells in Cord Blood TransplantationStatus unknownNCT01619761Phase 1
- Low Dose Chemotherapy With Aspirin in Patients With Breast Cancer After Neoadjuvant ChemotherapyStatus unknownNCT01612247Not applicable
- Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT01606241Phase 1
- Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung DiseaseCompletedNCT01570764Phase 3
- Iberoamerican Protocol With Thalidomide in Patients With Symptomatic Newly Diagnosed Multiple Myeloma Over 65 YearsStatus unknownNCT01532856Phase 3
- Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab Pateinets With Aggresive NHLCompletedNCT01527422Phase 1/2
- Docetaxel With or Without Metronomic Cyclophosphamide as First Line Chemotherapy in Metastatic Breast CancerStatus unknownNCT01526499Phase 2
- Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk PatientsCompletedNCT01516580Phase 3
- Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab EvaluationCompletedNCT01516567Phase 2
- HLA-haploidentical Hematopoietic Stem Cell Transplantation for Children and Adolescents With Acute Leukemia, Myelodysplastic Syndrome and Solid TumorsStatus unknownNCT01509300Phase 1/2